MITO - Stealth BioTherapeutics Corp
| Previous Close | 6.85 |
| Open | 6.88 |
| Bid | 6.91 x 1200 |
| Ask | 7.02 x 1000 |
| Day's Range | 6.76 - 7.02 |
| 52 Week Range | 4.97 - 20.99 |
| Volume | 28,958 |
| Avg. Volume | 37,364 |
| Market Cap | 242.08M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.67 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.17 |
- Zacks
Alexion (ALXN) Collaborates With Stealth BioTherapeutics
Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.
- Business Wire
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
Alexion Pharmaceuticals, Inc. (ALXN) and Stealth BioTherapeutics Corp (MITO) today announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) - a genetic mitochondrial disease - elamipretide is a novel, potential first-in-class therapy that targets mitochondrial dysfunction.
- PR Newswire
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
BOSTON, Oct. 7, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of pre-clinical data for its lead pipeline compound, SBT-272, at the 18th Annual Northeast Amyotrophic Lateral Sclerosis Consortium in Clearwater Beach, Fla. The data showed that treatment with SBT-272 was associated with a dose-dependent delay in the onset of neurological disease, a reduction in systemic markers of neurodegeneration and prolonged lifespan in a mouse model of amyotrophic lateral sclerosis (ALS). SBT-272, a mitochondrial targeting investigational molecule in pre-clinical development for the treatment of rare neurodegenerative diseases involving mitochondrial dysfunction, is expected to advance into Phase 1 first-in-man safety studies by year-end.
- PR Newswire
Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
BOSTON , Oct. 1, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...
- PR Newswire
Stealth BioTherapeutics to Attend Upcoming Investor Conferences
BOSTON , Sept. 20, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...
- Zacks
Stealth BioTherapeutics Enters Oversold Territory
Stealth BioTherapeutics Corp (MITO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Zacks
Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?
Stealth BioTherapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- PR Newswire
Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
BOSTON, Sept. 3, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the appointment of Robert Weiskopf as Chief Financial Officer (CFO). "We're delighted to welcome Rob to our team during this pivotal time in our growth trajectory," said Chief Executive Officer Reenie McCarthy.
- PR Newswire
Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights
- Louis Lange M.D., Ph.D. joins Board BOSTON , Aug. 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and ...
- PR Newswire
Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
BOSTON, July 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the Company will host a key opinion leader (KOL) breakfast symposium on Thursday, July 11, 2019 at 8:00 a.m. ET in New York City. The event will focus on the potential of the Company's lead candidate, elamipretide, in Primary Mitochondrial Myopathy and Barth's Syndrome and showcase data from its ongoing clinical programs, including data which was recently presented at Mitochondrial Medicine Symposium 2019, posters from which are now available on the Company's website.
- Zacks
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- PR Newswire
Stealth Biotherapeutics to Present at Upcoming Investor Conferences
BOSTON , May 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...
- PR Newswire
Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights
BOSTON , May 15, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...
- PR Newswire
Stealth BioTherapeutics to Present at UBS Global Healthcare Conference
BOSTON , May 14, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases ...
- PR Newswire
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions
BOSTON, April 30, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, recently presented positive results from its ophthalmic programs in dry age-related macular degeneration (AMD) and Leber's hereditary optic neuropathy (LHON). The data, which were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, being held April 28 – May 2 in Vancouver, British Columbia, demonstrated significant improvements in visual function following treatment with elamipretide, an investigational drug, in its ReCLAIM study of patients with dry AMD and in the open-label portion of its ReSIGHT study of patients with LHON.
- PR Newswire
Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
"The debilitating fatigue and muscle weakness due to primary mitochondrial myopathy often has a negative impact on the quality of life of affected patients," said Dr. Michio Hirano, professor of neurology at Columbia University Medical Center in New York, who enrolled the most patients across the 28 sites involved in the trial. Approximately 40,000 individuals in the U.S. have been diagnosed with PMM, a rare primary mitochondrial disease. There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of PMM.
- PR Newswire
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
BOSTON, April 16, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from the open-label extension of the Phase 2/3 TAZPOWER study of elamipretide, an investigational drug, in patients with genetically confirmed Barth syndrome. Barth syndrome is an ultra-rare mitochondrial disease in which reduced levels of the mitochondrial phospholipid cardiolipin are associated with skeletal muscle weakness, debilitating fatigue, cardiac abnormalities, recurrent infections, delayed growth and reduced life expectancy.
- PR Newswire
Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights
Completed initial public offering with gross proceeds of $85.1 million Dosed first patient in Phase 2b study of elamipretide in patients with dry AMD with geographic atrophy FDA interactions on Barth syndrome ...
- PR Newswire
Stealth BioTherapeutics to Present at H.C. Wainwright Global Life Sciences Conference
BOSTON , April 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases ...
- PR Newswire
Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD
BOSTON, March 28, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has dosed the first patient in ReCLAIM-2, a Phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy.
- Benzinga
BMO Bullish On 'Blockbuster Potential' Of Stealth BioTherapeutics' Lead Candidate
Stealth BioTherapeutics Corp (NASDAQ: MITO )'s lead drug elamipretide has “blockbuster potential” in primary mitochondrial dysfunction, or PMM, according to BMO Capital Markets. The Analyst BMO Capital ...
- PR Newswire
Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option
BOSTON, March 4, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has issued an additional 588,232 American Depositary Shares ("ADSs") at the public offering price of $12.00 per ADS, resulting in additional gross proceeds of approximately $7.1 million, pursuant to the exercise in part of the underwriters' over-allotment option in connection with Stealth's previously announced initial public offering of ADSs. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Stealth in the initial public offering was 7,088,232 ADSs and total gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Stealth, were approximately $85.1 million.
- Benzinga
IPO Outlook For The Week: Biotechs And Another Virgin Group Addition
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Anchiano Therapeutics Ltd. (ANCN) will issue 2.4 million shares at $14.55 ...
